Drug Trial Radar · NCT07741981
Treatment Resistance in Psychiatric Disorders: the Search for Biological Markers Predictive of Response to Treatment
Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
700
Planned (sponsor's estimate)
Start
Aug 20, 2026
Primary completion
Nov 1, 2036
Study completion Sep 1, 2038
Sponsor
- Lead sponsor
- Centre Hospitalier St AnneAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- GHU Paris Psychiatry & Neurosciences
- First posted
- Aug 3, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The disruption of immune system is a key candidate in the pathogenesis of psychiatric disorders, especially those resistant to traditional treatments. Involving complex processes within the brain and peripheral immune system, inflammation may lead to imbalance of neurotransmitter systems and synaptic plasticity and directly contribute to the psychiatric symptoms observed in conditions such as depression, bipolar disorder (BD) and schizophrenia (SCZ). Studies show that treatment-resistant depression (TRD) is associated with elevated levels of inflammatory markers in the blood, which are linked to a lower response to conventional antidepressants. Interventions that modulate this inflammatory response, such as immunomodulatory treatments or therapies targeting pro-inflammatory cytokines, have demonstrated beneficial effects by reducing symptoms and improving patients' quality of life. A thorough understanding of the links between inflammation and treatment resistance therefore paves the way for innovative therapeutic strategies. These approaches could transform current practices by offering more personalized and effective solutions for patients suffering from chronic and resistant psychiatric disorders.
Conditions
- Schizophrenia
- Treatment Resistant Depression (TRD)
- Bipolar Disorder (BD)
- Catatonia
- Obsessive Compulsive Disorder (OCD)
Interventions
Blood sampling, lumbar puncture, stool sampling, skin microbiopsy and psychometrics scalesBiological
the biomarker research involves different biological sampling : blood, stool, cerebrospinal fluid, skin
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes from inclusion (V1) in disease scale scores at the end of acute phase therapy (V3)Time frame: Up to 10 weeks
- Changes from inclusion (V1) in disease scale scores at the end of acute phase therapy (V3)Time frame: Up to 10 weeks
- Changes from inclusion (V1) in disease scale scores at the end of acute phase therapy (V3)Time frame: Up to 10 weeks
- Changes from inclusion (V1) in disease scale scores at the end of acute phase therapy (V3)Time frame: Up to 10 weeks
- Changes from inclusion (V1) in disease scale scores at the end of acute phase therapy (V3)Time frame: Up to 10 weeks
- Changes from inclusion (V1) in disease scale scores at the end of acute phase therapy (V3)Time frame: Up to 10 weeks
- Changes from inclusion (V1) in biological parameters at the end of acute phase therapy (V3).Time frame: Up to 10 weeks
- Changes from inclusion (V1) in biological parameters at the end of acute phase therapy (V3).Time frame: Up to 10 weeks
- Changes from inclusion (V1) in biological parameters at the end of acute phase therapy (V3).Time frame: Up to 10 weeks
- Changes from inclusion (V1) in biological parameters at the end of acute phase therapy (V3).Time frame: Up to 10 weeks
- Changes from inclusion (V1) in biological parameters at the end of acute phase therapy (V3).Time frame: Up to 10 weeks
- Changes from inclusion (V1) in biological parameters at the end of acute phase therapy (V3).Time frame: Up to 10 weeks
- Changes from inclusion (V1) in biological parameters at the end of acute phase therapy (V3).Time frame: Up to 10 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
GHU Paris - Psychiatrie et Neurosciences
Paris, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.